Maternal RSV Vaccine Study
• Now Open in Norfolk, NE
For infants, RSV is the leading cause of bronchiolitis and viral pneumonia and can be life-threating. In the U.S., RSV is the leading cause of infant hospitalization. Pregnant women age 19 to 49 may be eligible to receive an investigational RSV vaccine through a clinical study. The investigational vaccine would be administered to women at a gestational age (GA) of 24 to 33 weeks. Follow-up for this study (for the baby and mother) is expected to last one year.
Eligible participants…
- Must be pregnant and age 19 to 49
- Must have an uncomplicated pregnancy, and be at no known increased risk for complications, and have a fetus with no significant abnormalities observed on ultrasound
- Must be willing to participate in the study and follow up (for mother and child) for one year
- May receive compensation for time and travel
- May receive an placebo — this is a placebo-controlled study.
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.
You can also talk to a Meridian enrollment specialist about this study by calling (402) 934-7563.
Study Location(s)
Meridian Clinical Research
1410 N 13th St, Suite 5
Norfolk, NE 68701
See if You're Eligible...
About Meridian Clinical Research
Founded in 1999, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services.
Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For almost 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.
© 2018 MERIDIAN CLINICAL RESEARCH | Privacy Policy